N
6.76
0.19 (2.89%)
| Previous Close | 6.57 |
| Open | 6.49 |
| Volume | 2,102,044 |
| Avg. Volume (3M) | 2,067,453 |
| Market Cap | 395,608,064 |
| Price / Sales | 38.45 |
| Price / Book | 2.52 |
| 52 Weeks Range | |
| Earnings Date | 21 Nov 2024 |
| Operating Margin (TTM) | -535.86% |
| Diluted EPS (TTM) | -0.860 |
| Quarterly Revenue Growth (YOY) | 4.50% |
| Total Debt/Equity (MRQ) | 4.41% |
| Current Ratio (MRQ) | 5.16 |
| Operating Cash Flow (TTM) | -41.93 M |
| Levered Free Cash Flow (TTM) | -35.33 M |
| Return on Assets (TTM) | -17.15% |
| Return on Equity (TTM) | -31.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | NANO-X IMAGING LTD | Bearish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 0.75 |
|
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 8.99% |
| % Held by Institutions | 18.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Griffin Asset Management, Inc. | 30 Sep 2024 | 197,389 |
| Johnson & Johnson | 30 Sep 2024 | 158,852 |
| 52 Weeks Range | ||
| Median | 12.00 (77.52%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 06 Dec 2024 | 12.00 (77.51%) | Buy | 7.97 |
| 26 Nov 2024 | 11.00 (62.72%) | Buy | 6.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Dec 2024 | Announcement | Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication |
| 21 Nov 2024 | Announcement | Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update |
| 11 Nov 2024 | Announcement | Nanox to Report Third Quarter and Financial Results on November 21, 2024 |
| 31 Oct 2024 | Announcement | Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |